Analysis of left ventricular mass in untreated men and in men treated with agalsidase-beta: data from the Fabry Registry



: Germain DP, Weidemann F, Abiose A, Patel MR, Cizmarik M, Cole JA, Beitner-Johnson D, Benistan K, Cabrera G, Charrow J, Kantola I, Linhart A, Nicholls K, Niemann M, Scott CR, Sims K, Waldek S, Warnock DG, Strotmann J

Publisher: NATURE PUBLISHING GROUP

: 2013

 Genetics in Medicine

: GENETICS IN MEDICINE

: GENET MED

: 12

: 15

: 12

: 958

: 965

: 8

: 1098-3600

DOI: https://doi.org/10.1038/gim.2013.53


Conclusion: Agalsidase-beta treatment for >= 2 years may improve or stabilize left-ventricular mass in men with Fabry disease. Further investigations may determine whether early intervention and stabilization of LVM are correlated with clinical outcomes.


cardiomyopathy, enzyme replacement therapy, Fabry disease, lysosomal storage diseases, recombinant alpha-galactosidase A



Last updated on 26/11/2024 10:55:22 PM